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Abstract: Two simple, rapid, cost-effective and sensitive spectrophotometric 
procedures are proposed for the determination of hydroxyzine dihydrochloride 
(HDH) in pharmaceuticals and in spiked human urine. The methods are based 
on the charge transfer complexation reaction of the drug with either iodine (I2) 
as a σ-acceptor (method A) in dichloromethane or picric acid (PA) as a π- 
-acceptor (method B) in chloroform. The coloured products exhibit absorption 
maxima at 380 and 400 nm for I2 and PA, respectively. The Beer Law was 
obeyed over the concentration ranges of 1.25–15 and 3.75–45 μg mL-1 for me-
thod A and B, respectively. The molar absorptivity values, Sandell sensitivities, 
limits of detection (LOD) and quantification (LOQ) are reported. The accuracy 
and precision of the methods were evaluated on intra-day and inter-day basis. 
The proposed methods were successfully applied for the determination of HDH 
in tablets and spiked human urine.  
Keywords: hydroxyzine dihydrochloride; determination; spectrophotometry; 
charge-transfer complexation; pharmaceuticals; spiked urine. 
INTRODUCTION 
Hydroxyzine dihydrochloride (HDH), chemically known as 2-[2-[4-[(4-chlo-
rophenyl)phenymethyl]-1-piperazinyl]ethoxy]ethanol, dihydrochloride (Fig. 1), 
is an H1 receptor antagonist. It is widely used as an anxiolytic agent to control 
anxiety1 and anti-emetic.2 
The therapeutic importance of HDH initiated several reports on its determi-
nation both in pharmaceutical formulations and in biological fluids, viz. high-per-
formance liquid chromatography,3,4 gas chromatography,5 micellar liquid chro-
matography,6 capillary zone electrophoresis,7 voltammetry,8 LC–MS,9 potentio-
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metry10 and titrimetry.11–14 The United States Pharmacopoeia (USP)15 describes 
an HPLC method for the determination of HDH in tablets in which HDH is 
detected at 232 nm with a UV-detector. 
Fig. 1. Structure of hydroxyzine dihydrochloride. 
Few visible spectrophotometric methods12,16–18 have been reported for the 
determination of HDH in pharmaceuticals. In the method reported by Basavaiah 
and Charan,12 different concentrations of the drug are added to a fixed concen-
tration of Hg(II)-diphenylcarbazone complex and the decrease in the absorbance 
of the Hg(II)-diphenylcarbazone complex, as a consequence of the replacement 
of diphenylcarbazone in the complex by chloride from the drug, was measured at 
540 nm and the method is reported to be applicable in the range 0–60 µg mL–1. 
Sane et al.16 used three dyes for the determination of the drug content in phar-
maceuticals, the method being based on ion-pair formation. Marzanna et al.17 
employed Reinecke salt for the assay of the drug. A method based on the charge 
transfer complex formation reaction with chloranilic acid18 in acetonitrile was 
also reported. The method was less sensitive and HDH could be determined only 
in the concentration range 25–150 µg mL–1. 
The aim of the present study was directed at developing and validating two 
simple, rapid, sensitive and cost-effective spectrophotometric methods based on 
charge-transfer (C-T) complexation reactions using iodine and picric acid as σ-
and π-acceptors, respectively. In the first method (method A), the drug is reacted 
with iodine in dichloromethane to form a lemon yellow coloured C-T complex 
with an absorption maximum peaking at 380 nm. The second method (method B) 
employs picric acid as a π-acceptor to form a yellow C-T complex with the drug 
in chloroform and the absorbance of the complex is measured at 400 nm. The 
methods were successfully applied to quantify HDH in pharmaceutical formula-
tions and in spiked human urine. The results obtained were satisfactorily precise 
and accurate. 
EXPERIMENTAL 
Apparatus 
All absorption measurements were realised using a Systronics Model 106 digital spectro-
photometer with 1 cm path length quartz cells. 
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Materials 
Pharmaceutical grade HDH was procured from UCB Pharma Ltd., Mumbai, India, as a 
gift, and was used as received. Tablets containing HDH, Atarax 25 and Atarax 10 (UCB Phar-
ma Ltd., Mumbai, India) were purchased from the local market and used in the investigation. 
The urine sample was collected from a healthy volunteer (Male, around 27-year-old) and kept 
frozen until use after gentle thawing. Chloroform and dichloromethane (spectroscopic grade) 
were purchased from Merck, Mumbai, India. Distilled water was used wherever required. All 
other employed chemicals were of analytical reagent grade. 
Reagents 
A 0.5 % iodine solution was prepared by dissolving 1.25 g of pure resublimed iodine 
(S.D. Fine Chemicals Ltd., Mumbai, India) in 250 mL of dichloromethane and used after 30 
min. Picric acid (0.2 %) was prepared by dissolving 500 mg of pure substance (S.D. Fine 
Chemicals Ltd., Mumbai, India) in 250 mL of chloroform. To prepare 0.5 mol L-1 sodium 
hydroxide solution, an accurately weighed 2 g of pure NaOH (Merck, India) was dissolved in 
water, the solution was made up to 100 mL with water. 
Standard drug solution 
A 250-µg mL-1 solution of HDH was prepared by dissolving accurately weighed 25 mg 
of pure HDH in water and the volume was brought to 100 mL with water and mixed well. 
General recommended procedures 
Preparation of HDH base (HDN) solution. Method A: HDH solution (10 mL, 250 µg mL-
1) was transferred to a 125 mL separating funnel containing 10 mL of a 0.5 mol L-1 NaOH 
solution and the content was mixed well. The hydroxyzine base was extracted with three 15 
mL portion of dichloromethane, the extract was passed over anhydrous sodium sulphate and 
collected in a 100 mL volumetric flask, the volume was made up to the mark with dichloro-
methane and the resulting solution (25 µg mL-1 HDN) was used for the assay in method A. 
Method B: HDN solution (75 µg mL-1) was prepared by repeating the above procedure 
for 30 mL of pure HDH solution (250 µg mL-1) but chloroform was used instead of dichloro-
methane for extraction. The resulting solution was used for the assay in method B. 
Construction of the calibration curves. Method A: Varying aliquots of standard HDN 
solution equivalent to 1.25–15 µg mL-1 (0.25 – 3.0 mL of 25 µg mL-1) were accurately mea-
sured and transferred into a series of 5 mL calibrated flasks and 2 mL of 0.5 % iodine solution 
was added to each flask, the content was mixed well and the flasks were allowed to stand at 
room temperature (30±2 °C) for 15 min. The volume was brought to the mark with dichloro-
methane and the absorbance was measured at 380 nm against a reagent blank similarly pre-
pared but without the addition of HDN base solution. 
Method B. Into a series of 5 mL calibration flasks, aliquots (0.25–3.0 mL) of standard 
HDN solution (75 µg mL-1) equivalent to 3.75–45 µg mL-1 HDN were accurately transferred, 
and to each flask 1 mL of 0.2 % picric acid solution was added and the mixture was diluted to 
5 mL with chloroform. After 5 minutes, the absorbance of the yellow coloured C-T complex 
was measured at 400 nm against the reference blank similarly prepared. 
Procedure for commercial dosage forms 
Twenty tablets were weighed and pulverized. The amount of tablet powder equivalent to 
25 mg of HDH was transferred into a 100 mL volumetric flask. The content was shaken well 
with about 50 mL of water for 20 min, diluted to the mark with water and filtered through 
Whatmann No. 42 filter paper. The first 10 mL portion of the filtrate was discarded. HDN so-
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lutions of concentrations 25 and 75 µg mL-1 for method A and B, respectively, were prepared 
as described under the general procedures for pure drug and a suitable aliquot was used for 
assay by applying the procedures described earlier. 
Procedure for spiked human urine 
A spiked urine sample was prepared by adding 20 mg of pure HDH to 10 mL of urine in 
a separating funnel. Twenty mL of water was added, followed by 10 mL of 0.1 M NaOH 
solution and the mixture was extracted with three 15 mL portions of dichloromethane. The 
organic layer was passed over anhydrous sodium sulphate and collected in a 50 mL volu-
metric flask. The solution was made to the mark with dichloromethane and mixed well. The 
obtained solution was diluted appropriately to obtain a working concentration of 25 µg mL-1 
HDN. A 1–2 mL portion of the solution was then subjected to analysis as described for the 
pure drug in method A. For method B, the required volume of the base solution in dichlo-
romethane was evaporated to dryness. The residue was dissolved in chloroform and diluted 
with chloroform to a specific volume to obtain a working concentration of 75 µg mL-1 HDN. 
A portion of the solution (e.g., 2 mL) was used for the analysis by following the procedure 
described earlier. 
RESULTS AND DISCUSSION 
Molecular interactions between electron donors and electron acceptors are 
generally associated with the formation of intensely coloured charge-transfer 
complexes, which absorb radiation in the visible region.19 Charge transfer com-
plexation reactions have been extensively utilized for the determination of elec-
tron-donating basic nitrogenous compounds using either an σ-acceptor (iodi-
ne)20,21 or a π-acceptor (picric acid).19,22–27 The application of picric acid for 
the quantitative estimation of orphendrine citrate and phentolamine mesylate in-
jections listed in the USP.28 
Spectral characteristics 
HDN, an n-donor (D), forms a lemon yellow-coloured C-T complex with 
iodine (I2) (σ-acceptor) in dichloromethane and the resulting coloured species 
was found to absorb maximally at 380 nm (Fig. 2). The colour of iodine in di-
chloromethane is violet showing absorption maximum (λmax) at 500 nm. This 
colour changed into lemon yellow when the iodine was mixed with the drug, and 
showed an absorption peak at 380 nm (Fig. 2). HDN reacts with picric acid in 
chloroform medium to yield a yellow-coloured C-T complex peaking at 400 nm 
(Fig. 3). The interactions between HDN and acceptors to form charge transfer 
complexes follows according to Schemes 1 and 2. 
Optimization of the reaction conditions 
Optimum conditions were established by measuring the absorbance of C-T 
complexes at 380 and 400 nm, for method A and B, respectively, by varying one 
parameter at a time and keeping the others constant. 
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Fig. 2. Absorption spectra of the HDN–I2 C-T complex (15 µg mL-1 HDN) 
and the reagent blank. 
 
Scheme 1. Reaction pathway for the formation of the C-T complex 
between HDN and I2 in dichloromethane 
 
Scheme 2. Reaction pathway for the formation of the electron donor–acceptor 
complex and radical ions between HDN and picric acid. 
Effect of reagent concentration. To establish optimum amounts of the re-
agents for the sensitive and rapid formation of the HDN charge transfer com-
plexes, the drug (HDN) was allowed to react with different volumes of the re-
agents (1–4 mL of 0.5 % iodine and 1–3 mL of 0.2 % picric acid in method A 
and B, respectively). At 2 mL of iodine and 1 mL of picric acid, maximum and 
minimum absorbance values with respect to the sample and blank were obtained 
for method A and B, respectively. Therefore, 2 mL of 0.5 % iodine and 1 mL of 
0.2 % picric acid in a total volume of 5 mL were used throughout the following 
investigations. 
Choice of solvent. Acetonitrile, chloroform, dichloromethane, ethanol, 2-pro-
panol, methanol, benzene and 1,4-dioxane were the evaluated solvents. Dichloro-
methane was found to be the ideal solvent for I2 and showed superior properties 
compared to the other solvents, since it is favourable for the formation of the tri-
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iodide ion-pair (inner complex). With I2, the other solvents produced lower ab-
sorption readings for the sample and higher absorption values for the blanks. In 
method B, chloroform afforded the maximum sensitivity when compared with all 
the investigated solvents. Hence, dichloromethane and chloroform were used as 
solvents for method A and B, respectively.  
Reaction time and stability. Complete colour development of the C-T com-
plex was attained after 15 and 5 min in method A and B, respectively, and the 
coloured species were stable for at least 1 and 16 h, respectively.  
Composition of the C-T complexes 
The composition of the C-T complex was established by the Job method of 
continuous variations29 using equimolar concentrations of the drug (base form) 
and reagents (4.28×10–4 mol L–1 in method A and 2.43×10–4 mol L–1 in method 
B). The results indicated that a 1:1 (drug:reagent) complex is formed in both cases. 
Method validation 
A linear correlation was found between the absorbance at λmax and the 
concentration of HDH in the ranges given in Table I. Regression analysis of the 
Beer Law data using the least squares method was performed to evaluate the 
slope (b), intercept (a) and the correlation coefficient (r) for each system and the 
values are presented in Table I. The optical characteristics such as the limits of 
the Beer Law, molar absorptivity and the Sandell sensitivity values of both me-
thods are also given in Table I. In addition, the limits of detection (LOD) and 
quantification (LOQ), calculated according to ICH guidelines,30 are also pre-
sented in Table I. 
TABLE I. Sensitivity and regression parameters 
Parameter  Method A  Method B 
λmax / nm  380  400 
Colour stability, h  1  16 
Linear range, µg mL
-1 1.25–15  3.75–45
 
Molar absorptivity (ε), L mol
-1 cm
-1 2.59 x 10
4 8.06 x 10
3 
Sandell sensitivity, µg cm
-2  0.0172 0.0556 
LOD / µg mL
-1 0.13  0.62 
LOQ / µg mL
-1 0.39  1.88 
Regression equation, Y
a
Intercept (a) 0.0093  0.0113 
Slope (b) 0.0565  0.0174 
Standard deviation of a (Sa) 0.0998  0.0998 
Standard deviation of b (Sb) 0.0095  0.0030 
Regression coefficient (r) 0.9993  0.9995 
aY = a + bX, where Y is the absorbance, X is concentration in µg mL-1, a is the intercept and b is the slope 
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Precision and accuracy 
For three levels of analyte, the assays were repeated seven times within a 
day to determine the intra-day precision and five times on different days to de-
termine the inter-day precision of the methods. The percentage relative standard 
deviation (RSD) values were ≤2.29 % (intra-day) and ≤2.98 % (inter-day), indi-
cating the high precision of the methods. The accuracy was evaluated as the per-
centage relative error (RE) between the measured mean concentrations and the 
taken concentrations for HDN. The RE values of ≤2.40 % demonstrate the high 
accuracy of the proposed methods. 
Robustness and ruggedness 
The robustness of the methods was evaluated by making small incremental 
changes in the volume of reagent (2±0.2 mL of I2; 1±0.2 mL of PA) and contact 
time (5±2 min in method B), and the effect of the changes was studied on the ab-
sorbance of the complex systems. The changes had negligible influence on the 
results as revealed by small intermediate precision values expressed as % RSD 
(≤3 %). Method ruggedness was demonstrated by having the analysis performed 
by four analysts, and by a single analyst performing the analysis on four different 
instruments in the same laboratory. The intermediate precision values (RSD) in 
both instances were in the range 1.62–3.16 %, indicating acceptable ruggedness. 
Applications 
Commercial tablets. The proposed methods were applied for the quantifi-
cation of HDH in commercial tablets. The results were compared with those 
obtained by the US Pharmacopoeial method.15 Statistical analysis of the results 
did not detect any significant difference between the performance of the pro-
posed methods and reference method with respect to accuracy and precision as 
revealed by the Student’s t-value and variance ratio F-value. The results of the 
assay are given in Table II. 
TABLE II. Results of analysis of tablets by the proposed methods and statistical comparison 
of the results with the reference method 
Tablet brand name
  Nominal amount 
mg/tablet 
Found
a (Percent of label claim ± SD) 
Reference method  Method A  Method B 
Atarax 25
 
25 99.16±0.88 
100.6±1.36
t = 2.03
b 
F = 2.39
c 
101.3±1.56 
t = 2.77 
F = 3.14 
Atarax 10
 
10 101.6±1.2 
100.6±0.96
t = 1.46 
F = 1.56 
99.62±1.09 
t = 2.73 
F = 1.21 
aMean value of 5 determinations; 
btabulated t-value at the 95 % confidence level and for four degrees of 
freedom is 2.77; 
ctabulated F-value at the 95 % confidence level and for four degrees of freedom is 6.39 
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Recovery from spiked human urine. As another application of the proposed 
methods, recovery from human urine samples was performed. A prior extraction 
step, according to Mehran et al.31 was used. The recovery studies were realised 
with samples containing various amounts of HDN. The results of recovery stu-
dies revealed that the other constituents present in the urine did not interfere in 
the method. The recovery values were in the range 97.2–108.6 %. 
Recovery from tablet powder. The recovery test was performed by spiking 
the pre-analyzed tablet powder with pure HDH at three different levels (50, 100 
and 150 % of the content present in the tablet powder (taken) and the total was 
found by the proposed methods. Each test was repeated three times. In all the 
cases, the recovery values ranged between 98.40 and 105 %, with a standard de-
viation in the range 1.04–1.85 %. The closeness of the results to 100 % showed 
the fairly good accuracy of the methods. 
CONCLUSIONS 
Two simple, sensitive, extraction-free, rapid and cost-effective spectrophoto-
metric methods based on charge transfer complex formation reactions for the de-
termination of HDH were developed and validated. The suggested methods uti-
lize a single step reaction and single solvent. No substantial differences among 
the proposed methods arose from analysis of the experimental results. The me-
thods are free from interferences from the common excipients and additives. The 
statistical parameters and the recovery data reveal good accuracy and precision of 
the methods. These methods, which can be used as general methods for the deter-
mination of HDH in bulk powder, dosage forms and spiked human urine, have 
many advantages over the separation techniques, e.g., HPLC, such as reduced 
cost, and speed with high accuracy. Hence, the methods can be used in the rou-
tine analysis of drugs in quality control laboratories. 
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ИЗВОД 
ОПТИМИЗОВАНА И ВАЛИДИРАНА МЕТОДА ЗА СПЕКТРОФОТОМЕТРИЈСКО 
ОДРЕЂИВАЊЕ ХИДРОКСИЗИН-ХИДРОХЛОРИДА У ФАРМАЦЕУТСКИМ 
ПРЕПАРАТИМА И УРИНУ УЗ КОРИШЋЕЊЕ ЈОДА И ПИКРИНСКЕ КИСЕЛИНЕ 
NAGARAJU RAJENDRAPRASAD, KANAKAPURA BASAVAIAH и KANAKAPURA B VINAY 
Department of Studies in Chemistry, Manasagangothri, University of Mysore, Mysore 570 006, India 
Предложене су две економичне и осетљиве спектрофотометриске процедуре за одређи-
вање  хидроксизин-дихидрохлорида (HDH) у  фармацеутским  препаратима  и  оптерећеном 
урину. Метода се заснива на трансферу наелектрисдања комплексометријске реакције у леку 
са јодом као σ-акцептором (мeтoда A) у дихлор-метану и са пикринском киселином као π-aк-
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цептором (метода Б) у хлороформу. Обојени производи имају апсорпционе максимуме на 
380 and 400 nm за I2 и пикринску киселину. Сагласност са Beer-овим законом је постигнута у 
опсегу концентрација 1,25–15 и 3,75–45 µg mL-1, за обе методе. Дате су вредности моларне 
апсорптивности, Санделовог индекса, граница детекције и квантификације и евалуирана тач-
ност и прецизност методе. Предложене методе су успешно примењене за одређивање HDH у 
таблетама и оптерећеном хуманом урину. 
(Примљено 7. октобра 2010, ревидирано 9. фебруара 2011) 
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